Payment overview · 2025
General Payments
$646.87
13 reported records · 5 companies
Healthcare provider profile · identity verified
Amos Charles Johnson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SOUTHFIELD, MI · NPI 1801805270
Verified facts
What the public records show
CMS Open Payments records show Amos Charles Johnson, M.D. received $646.87 in general payments during 2025 across 13 reported records.
Amgen Inc. accounted for 45.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Edarbyclor by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Kerendia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $295.65 | 45.7% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $145.67 | 22.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $134.63 | 20.8% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.19 | 7.8% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.73 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $646.87 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $295.65 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $145.67 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $134.63 | 2 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $50.19 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.17 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 143 | 14 |
| Atorvastatin Calcium | Atorvastatin Calcium | 113 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 112 | 30 |
| Omeprazole | Omeprazole | 111 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 101 | 23 |
| Trulicity | Dulaglutide | 83 | 12 |
| Simvastatin | Simvastatin | 61 | 12 |
| Losartan Potassium | Losartan Potassium | 60 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 13 |
| Allopurinol | Allopurinol | 49 | 11 |
| Ezetimibe | Ezetimibe | 48 | 14 |
| Atenolol | Atenolol | 47 | 12 |
| Gabapentin | Gabapentin | 44 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 42 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 15 |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Indapamide | Indapamide | 39 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Azithromycin | Azithromycin | 37 | 24 |
| Naproxen | Naproxen | 36 | suppressed |
| Metformin Hcl | Metformin Hcl | 35 | suppressed |
| Kerendia | Finerenone | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 29 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | suppressed |
| Furosemide | Furosemide | 26 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 26 | suppressed |
| Repaglinide | Repaglinide | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 20 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $646.87 · 13 records | Amgen Inc. | AZMIRO, Kerendia, OTEZLA, QULIPTA, REPATHA, UBRELVY, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error